Market Analysis Report Stomach Cancer Market 2019 | страница 2

Cancer Market is classified hospitals, clinics, specialized cancer treatment centers and ambulatory
surgical centers.
Regionally, Asia-Pacific followed by Latin America is the most important markets for Stomach Cancer
Treatment due to the large patient pool in case of stomach cancer. Whereas, Gastric Cancer Treatment
Market in regions such as North America and Africa are projected to witness slow growth owing to low
occurrence rate of stomach cancer.
Major Players profiled in the Stomach Cancer Market report incorporate: Eli Lilly and company, F.
Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck KGaA, Novartis International AG and Otsuka
Holdings Co. Ltd.
Latest Industry News
1 Novartis announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib,
formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and
men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-
), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test
following progression on or after an endocrine-based regimen
PIK3CA is the most commonly mutated gene in HR+/HER2- breast cancer; approximately 40% of patients
living with HR+/HER2- breast cancer have this mutation[8],[10]. PIK3CA mutations are associated with
tumor growth, resistance to endocrine treatment and a poor overall prognosis. Piqray targets the effect
of PIK3CA mutations and may help overcome endocrine resistance in HR+ advanced breast cancer.
2 TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced
today the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with
recurrent or advanced endometrial cancer who progressed on or after a platinum-based regimen. These
data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s
Cancer in Honolulu, Hawaii. The preliminary results demonstrate clinically meaningful and durable
response rates of dostarlimab (anti-PD-1 antibody, formerly TSR-042), in this patient population,
regardless of microsatellite instability status. In addition, the safety findings indicate that dostarlimab is
well tolerated with a safety profile consistent with what is expected of anti-PD-1 therapy.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162984 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Stomach Cancer in these regions, from 2014 to 2023 (forecast), covering:
North America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.